Acrivon Therapeutics (NASDAQ:ACRV) CFO Adam Levy Acquires 8,832 Shares

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) CFO Adam Levy purchased 8,832 shares of the stock in a transaction that occurred on Wednesday, January 14th. The shares were acquired at an average cost of $1.70 per share, for a total transaction of $15,014.40. Following the completion of the transaction, the chief financial officer owned 20,983 shares of the company’s stock, valued at $35,671.10. This trade represents a 72.69% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Acrivon Therapeutics Trading Up 5.9%

NASDAQ:ACRV traded up $0.11 on Friday, hitting $1.98. The company had a trading volume of 1,997,999 shares, compared to its average volume of 5,854,625. The stock has a market capitalization of $62.49 million, a price-to-earnings ratio of -0.93 and a beta of 1.73. Acrivon Therapeutics, Inc. has a 52 week low of $1.05 and a 52 week high of $8.00. The firm has a 50 day moving average of $2.30 and a two-hundred day moving average of $1.82.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.10. As a group, equities analysts forecast that Acrivon Therapeutics, Inc. will post -2.49 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ACRV. Weiss Ratings reiterated a “sell (d-)” rating on shares of Acrivon Therapeutics in a research report on Monday, December 29th. Piper Sandler lifted their target price on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Wall Street Zen cut Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price on shares of Acrivon Therapeutics in a research note on Tuesday, November 25th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Acrivon Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Invesco Ltd. purchased a new position in shares of Acrivon Therapeutics in the 1st quarter valued at $72,000. XTX Topco Ltd purchased a new stake in shares of Acrivon Therapeutics in the 2nd quarter valued at $126,000. Quadrature Capital Ltd acquired a new stake in Acrivon Therapeutics during the 2nd quarter worth about $26,000. Jane Street Group LLC purchased a new position in Acrivon Therapeutics during the second quarter valued at approximately $371,000. Finally, UBS Group AG boosted its position in Acrivon Therapeutics by 150,057.8% in the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock worth $1,237,000 after purchasing an additional 682,763 shares in the last quarter. Hedge funds and other institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.